BioCentury
ARTICLE | Clinical News

AZ, Lilly BACE inhibitor moves ahead in AD study

April 9, 2016 1:23 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Eli Lilly and Co. (NYSE:LLY) said the ongoing Phase II/III AMARANTH study of AZD3293 ( LY3314814) to treat early Alzheimer's disease will advance to its Phase III segment on the recommendation of an IDMC. The milestone triggers a $100 million payment to AZ from Lilly.

The committee conducted an interim safety analysis and did not evaluate efficacy of the oral beta-site APP-cleaving enzyme 1 ( BACE1) and BACE2 inhibitor. ...